Reports Complete Response in First Infant with ECUR-506 for OTC Deficiency, iECURE iECURE, Inc., a gene-editing company focused on developing in vivo gene insertion therapies for liver disorders, reports promising…
Cofactor Genomics Announces CEO Change for Growth and OncoPrism Expansion Cofactor Genomics, Inc., a leader in precision medicine through RNA decoding, has appointed Chris Parker as CEO and Board Member…
Vir Biotechnology Reports Positive Data in Ongoing Trials for VIR-5818 and VIR-5500 Vir Biotechnology, Inc. (Nasdaq: VIR) has presented encouraging preliminary Phase 1 data from two of its dual-masked T-cell…
Phase 3 Studies for Azafaros Receive Key Regulatory Approvals, Set to Begin in 2025 Azafaros B.V. today revealed that its leading asset, nizubaglustat, has received Orphan Drug Designation (ODD) from…
Partnering for Bispecific Antibodies and ADCs: Biocytogen and Acepodia Biocytogen (HKEX: 02315) and Acepodia (6976:TT) have announced a strategic partnership aimed at jointly evaluating a dual-payload bispecific antibody-drug conjugate (BsAD2C)…
Heart Failure Program and Leadership Change Announced by RyCarma RyCarma Therapeutics, Inc., formerly known as ARMGO Pharma, is a clinical-stage biotech company focused on developing first-in-class small molecule therapeutics for…
Esophagus Test TissueCypher® Receives NY State Approval, Announces Castle Biosciences Castle Biosciences, Inc. (Nasdaq: CSTL), a leading company in providing innovative tests to guide patient care, has announced that its…
TruBridge Appoints Merideth Wilson as GM of Financial Health TruBridge, Inc. (NASDAQ: TBRG), a leading provider of healthcare solutions, has announced the appointment of Merideth Wilson as the new Financial…
Verastem Unveils Critical FDA Review of Avutometinib-Defactinib for Ovarian Cancer Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company dedicated to advancing new cancer treatments, has announced that the U.S. Food and…
Takeda Announces HYQVIA® 10% Injection Approval in Japan for Agammaglobulinemia Takeda (TSE:4502/NYSE:TAK) has announced that the Japanese Ministry of Health, Labour and Welfare has approved HYQVIA® [Immune Globulin Infusion 10%…
Allurion Technologies Announces Reverse Stock Split Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, has announced that its Board of Directors has approved a one-for-twenty-five reverse stock…
Clinical Trials: Ellipse Launches Program in the Middle East Ellipses Pharma Limited, a global drug development company focused on advancing cancer treatments, has launched its first large-scale Phase 1/2 oncology…